Molecular and clinical diversity in primary central nervous system lymphoma - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Annals of Oncology Année : 2022

Molecular and clinical diversity in primary central nervous system lymphoma

(1) , (1) , (2, 3) , (1, 4) , (5) , (6, 7) , (8) , (9) , (10) , (11) , (12, 13, 14) , (14) , (15, 16) , (15) , (17, 18) , (19) , (20) , (21) , (8) , (22, 23) , (24) , (1) , (25, 4) , (25, 4) , (26) , (1, 4) , (1, 4) , (4, 25) , (25, 4) , (4, 25) , (27) , (28) , (4, 25) , (29) , (4, 25) , (3, 2) , (1, 4) , (1, 4)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
J.-P. Marolleau
  • Fonction : Auteur
  • PersonId : 887235
  • IdRef : 06981676X

Résumé

Background: Primary central nervous system lymphoma (PCNSL) is a rare and distinct entity within diffuse large B cell lymphoma presenting with variable response rates probably to underlying molecular heterogeneity. Patients and methods: To identify and characterize PCNSL heterogeneity and facilitate clinical translation, we performed a comprehensive multi-omic analysis (whole-exome sequencing, RNA-seq, methyl-seq, and clinical features) in a discovery cohort of 147 fresh-frozen immunocompetent PCNSLs and a validation cohort of formalin-fixed, paraffin-embedded (FFPE) 93 PCNSLs with RNA-seq and clinico-radiological data. Results: Consensus clustering of multi-omics data uncovered concordant classification of four robust, non-overlapping, prognostically significant clusters (CS). The CS1 and CS2 groups presented an immune-cold hypermethylated profile but distinct clinical behavior. The "immune-hot" CS4 group, enriched with mutations increasing the JAK-STAT and NF-κB activity, had the most favorable clinical outcome while the heterogeneous-immune CS3 group had the worse prognosis probably due to its association with meningeal infiltration and enriched HIST1H1E mutations. The CS1 was characterized by high Polycomb repressive complex 2 activity and CDKN2A/B loss leading to higher proliferation activity. Integrated analysis on proposed targets suggests potential use of immune checkpoint inhibitors/JAK1 inhibitors for CS4, cyclin D-Cdk4,6 plus PI3K inhibitors for CS1, lenalidomide/demethylating drugs for CS2, and EZH2 inhibitors for CS3. We developed an algorithm to identify the PCNSL subtypes using RNA-seq data from either FFPE or FF tissue. Conclusions: The integration of genome-wide data from multi-omics data revealed four molecular patterns in PCNSL with a distinctive prognostic impact that provides a basis for future clinical stratification and subtype-based targeted interventions.

Dates et versions

hal-03870175 , version 1 (24-11-2022)

Identifiants

Citer

I. Hernández-Verdin, E. Kirasic, K. Wienand, K. Mokhtari, S. Eimer, et al.. Molecular and clinical diversity in primary central nervous system lymphoma. Annals of Oncology, 2022, ⟨10.1016/j.annonc.2022.11.002⟩. ⟨hal-03870175⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More